GlassScriptPhysician profile
Guy N Yatsushiro
NPI 1528183217
$21,594.86
in general payments reported to CMS, 2019-2025
42 companies · $2,030 in 2025
The $2,030 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,752 · 2020: $3,186 · 2021: $4,160 · 2022: $3,071 · 2023: $2,978 · 2024: $2,418 · 2025: $2,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,066 · Education: $185 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,065.63 |
| Education | $184.87 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,235.50 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amarin Pharma, INC. | $2,238.88 | 2019-2023 | |
| Glaxosmithkline, LLC. | $1,838.44 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $1,451.28 | 2019-2025 | Krystexxa, Prolia, Repatha |
| Novo Nordisk INC | $1,356.78 | 2019-2025 | Ozempic, Rybelsus |
| Csl Behring | $1,334.32 | 2019-2025 | Haegarda, Andembry, Kcentra |
| Biocryst US Sales Co., LLC | $1,060.55 | 2021-2025 | Orladeyo |
| Lilly USA, LLC | $1,052.80 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Sanofi-Aventis U.S. LLC | $807.46 | 2019-2023 | |
| Pharming Healthcare, INC. | $801.02 | 2019-2025 | Ruconest |
| Bayer Healthcare Pharmaceuticals INC. | $689.37 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $624.53 | 2020-2025 | Takhzyro, Entyvio |
| Janssen Pharmaceuticals, INC | $584.87 | 2019-2024 | Xarelto |
| Jazz Pharmaceuticals INC. | $473.87 | 2019-2022 | |
| Pfizer INC. | $467.73 | 2019-2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.23 | 2019-2024 | Jardiance, Synjardy, Stiolto Respimat |
| Esperion Therapeutics, INC. | $365.78 | 2020-2025 | Nexletol |
| Abbott Laboratories | $289.07 | 2021-2025 | Freestyle Libre 3 |
| Shire North American Group INC | $287.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $276.18 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $249.68 | 2021-2024 | Livalo, Zoryve, Seglentis |
| Dexcom, INC. | $243.75 | 2023-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $206.04 | 2019-2021 | |
| Abbvie INC. | $172.53 | 2019-2021 | |
| Allergan, INC. | $144.52 | 2019-2020 | |
| Biocryst Pharmaceuticals, INC. | $140.44 | 2020 | |
| Sunovion Pharmaceuticals INC. | $124.71 | 2019 | |
| Horizon Therapeutics Plc | $109.36 | 2021-2023 | Krystexxa |
| Ionis Pharmaceuticals, INC. | $81.36 | 2025 | Dawnzera |
| Genentech USA, INC. | $69.81 | 2019-2021 | |
| Exact Sciences Corporation | $61.39 | 2024-2025 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $47.76 | 2020 | |
| Radius Health, INC. | $42.80 | 2019 | |
| Merck Sharp & Dohme LLC | $41.70 | 2019-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Inspire Medical Systems, INC. | $39.54 | 2024 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.31 | 2025 | Caplyta |
| Arbor Pharmaceuticals, INC. | $32.02 | 2019-2020 | |
| Astellas Pharma US INC | $23.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.53 | 2025 | Eliquis |
| Insulet Corporation | $19.97 | 2025 | Omnipod |
| Eisai INC. | $17.36 | 2021 | |
| Leo Pharma INC. | $15.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Yatsushiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.